To assess the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of single and multiple ascending oral doses of CKD-504 compared to placebo in healthy Korean and Caucasian adult subjects
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
88
Seoul National University Hospital
Seoul, South Korea
RECRUITINGCmax of CKD-504
Peak Plasma Concentration (Cmax) of CKD-504
Time frame: Day1, Day2, Day3, Day4
AUC of CKD-504
Area under the plasma concentration versus time curve (AUC) of CKD-504
Time frame: Day1, Day2, Day3, Day4
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.